Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

Bárcena‐Varela, Marina, Caruso, Stefano, Llerena, Susana, Álvarez‐Sola, Gloria, Uriarte, Iker, Latasa, M. Ujue, Urtasun, Raquel, Rebouissou, Sandra +18 more·2019·Hepatology
DOI 10.1002/hep.30168

Cited by (131)

Items 101–131 of 131

  1. Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma
    Elena Adán-Villaescusa, Borja Castelló-Uribe, Iker Uriarte, Eva Santamaría, Roberto Barbero, Miriam Belzunce, Amaya López-Pascual, Maria Ujue Latasa, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya et al. · 2026 · Cell Reports Medicine
  2. Epigenetic Reprogramming of the Glucose Metabolic Pathways by the Chromatin Effectors During Cancer
    Payel Mondal, Niharika Tiwary, Amrita Sengupta, Sinjini Dhang, Siddhartha Roy, Chandrima Das · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
  3. Mechanotransduction-Epigenetic Coupling in Pulmonary Regeneration: Multifunctional Bioscaffolds as Emerging Tools
    Jing Wang, Anmin Xu · 2025 · Pharmaceuticals
  4. Hepatoblastoma‐Derived Exosomal FASN Affected the Differentiation of Hepatic Stellate Cells Into Cancer‐Associated Fibroblasts by Regulating the Stability of HK2 and Mediating Histone Lactylation
    Qin Zhu, Yi-Fan Zhou, Y.J. Wang, Xinyu Wu, Yiguo Hu, Hongyan Zai · 2025 · Comprehensive physiology
  5. Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma
    Wei Ouyang, Ming-Da Wang, Wanyin Wang, Chao Li, Lan‐Qing Yao, Hong Zhu, Tian Yang · 2023 · Journal of Oncology
  6. SUV39H1 Inhibits Angiogenesis in Limb Ischemia of Mice
    Wenhao Niu, Wenyue Cao, Feng Go Ho Wu, Chun Liang · 2023 · Cell Transplantation
  7. Discovery of 2-tetrahydroisoquinoline substituted quinazoline derivatives as lysine methyltransferase G9a inhibitors with in vivo antitumor efficacy
    Mengjie Shao, Lixin Gao, Jiahui Xu, Lingfeng Zhu, Yiting Lu, Kailong Jiang, Jia Sun, Xiaolong Jiang, Lee Jia, Ao Zhang et al. · 2025 · European Journal of Medicinal Chemistry
  8. MDM2 and DNMT1 inhibitors induce neuroblastoma cell death through p53-dependent and independent pathways
    Shyam Sundar Jaganathan, Umamaheswari Natarajan, Appu Rathinavelu · 2025 · Epigenomics
  9. The Roles of Epigenetic Regulators and Inflammasome in Hepatocellular Carcinoma Tumorigenesis in Patients with Alcoholic Steatohepatitis (ASH) vs Non-Alcoholic Steatohepatitis (NASH)
    Yue Jia · 2019 · Clinical Oncology and Research
  10. Epigenetics in hepatoblastoma
    Alex Clavería-Cabello, María Arechederra, Carmen Berasain, Maite G. Fernández‐Barrena, Matias Antonio Avila · 2021 · Hepatoma Research
  11. Papel de SLU7 en la regulación epigenética de la expresión génica: control de la estabilidad de DNMT1 y la metilación del DNA
    Miriam Recalde · 2022
  12. KAIMRC’S Second Therapeutics Discovery Conference
    Zeyad Alehaideb, Nimer Mehyar, Mai Al Ajaji, Mohammed Alassiri, Manal A. Alaamery, Bader Al Debasi, Bandar Alghanem, Jahad Alghamdi, Bahauddeen M. Alrfaei, Barrak Al Somaie et al. · 2020
  13. Epigenetic modifications and regulations in gastrointestinal diseases
    Aditi Bhattacharya · 2023 · Elsevier eBooks
  14. The Increasing Relevance of Histone Lysine Methylation for Hepatocellular Carcinoma Pathogenesis and Treatment
    Teresa Rubio‐Tomás · 2021 · Advanced Research in Gastroenterology & Hepatology
  15. Epigenetics in the Diagnosis, Prognosis, and Therapy of Cancer
    Leilei Fu, Bo Liu · 2023 · Epigenetics and human health
  16. Inhibitors of Epigenetic Modulators as Therapeutic Alternatives for Cardiovascular Diseases
    Gustavo Adolfo Barraza, Wendy Rosales, Carlos Mario Meléndez · 2025 · Mini-Reviews in Medicinal Chemistry
  17. Discovery of a Novel G9a-Selective Inhibitor for Hepatocellular Carcinoma Treatment
    Xiaoyu Mu, Jiao Li, Rong Wei, Jiankang Zhou, Yue Ming, Hulin Ma, Fuyan Xu, Xiaomin Xu, Wenchen Pu, Yong Peng · 2025 · ACS Medicinal Chemistry Letters
  18. Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma
    Amaya López-Pascual, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya, Maria Ujue Latasa, Elena Anaya, Elena Adán-Villaescusa, Borja Castelló-Uribe, Luz Andrea Martínez‐Pérez, Iker Uriarte, María Arechederra et al. · 2026 · Frontiers in Cell and Developmental Biology
  19. Additional file 1 of DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma
    Liu, Yangfan, Yu Sun, Jin Yang, Deyang Wu, Yu, Shuang, Junjiang Liu, Hu, Tao, Luo, Jingjing, H. Zhou · 2024 · Figshare
  20. Additional file 2 of DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma
    Liu, Yangfan, Yu Sun, Jin Yang, Deyang Wu, Yu, Shuang, Junjiang Liu, Hu, Tao, Luo, Jingjing, H. Zhou · 2024 · Figshare
  21. Trefoil Factor‐3 Is a Hypoxia‐Triggered Pro‐Tumorigenic Factor in Hepatoblastoma
    L. A. Martínez-Pérez, M. Latasa, I. Uriarte, A. López-Pascual, J. Elurbide, Pavel Strnad, S. Fraňková, Eva Sticová, Ondřej Fabián, M. Arechederra et al. · 2026 · Liver international (Print)
  22. Targeting UHRF1 induces regression of aggressive mantle cell lymphoma
    Yuan Yang, Zengwei Tang, Qinglin Hu, Ping Yang, Weilong Zhang, Jing Wang, Hongmei Jing · 2026 · Leukemia
  23. Glucocorticoid receptor activity in triple negative breast cancer
    Lara Malik Noureddine · 2022
  24. Recent Advances in Searching for DNMT Inhibitors and Their Potential Application in Treating Human Diseases
    Anatoly A. Bulygin, Anastasiia T. Davletgildeeva, Nikita A. Kuznetsov · 2026 · International Journal of Molecular Sciences
  25. Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets
    Chunwei Li, Z H Liu, Dezheng Kong, Zhengze Li, Yiming Yan, Yanyu Dong, Lili Zhu, Jianing Cao, Zhirui Fan, Gautam Sethi et al. · 2026 · MedComm
  26. Crosstalk between epigenetic regulation and metabolic reprogramming in hepatocellular carcinoma
    Yicheng Pu, Yue Lv, Zhen Wang, Kefei Yuan · 2026 · Chinese Medical Journal
  27. Decitabine suppresses triple-negative breast cancer by disrupting DNMT1 liquid-liquid phase separation and synergizes with G9a inhibition
    Meilin Hu, Haojie Peng, Qiu Guochang, Sen Liu, Qianying Li, Taizhen Liang, Jintao Lai, Fenmei Liang, Yiqiang Zhu, Xiaoqing Liu et al. · 2026 · Oncogene
  28. G9a blockade uncovers therapeutic vulnerabilities in advanced prostate cancer
    Marianna Kruithof‐de Julio, Filipa Moreira‐Silva, Catarina Macedo‐Silva, Marc Zimmerli, Irena Klima, Beat Roth, Panagiotis Chouvardas, Cármen Jerónimo · 2026 · Research Square
  29. The epigenetic landscape of hepatocellular carcinoma: from molecular mechanisms to early detection biomarkers and precision therapy
    Shraddha Dubey, Himanshu Gupta · 2026 · Gene
  30. BindingDB Entry 50009105: Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
    BindingDB · 2021 · UC San Diego
  31. BindingDB Entry 50022931: G9a/GLP Modulators: Inhibitors to Degraders.
    BindingDB · 2026 · UC San Diego